Posts

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

/in

LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ Link here — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 […]

Read more

CalciMedica Expands Executive Team with New Appointments

/in

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) — Link here: CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the appointments of […]

Read more

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

/in

LA JOLLA, Calif., March 20, 2023 (GLOBE NEWSWIRE): News Link – CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” – Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 – Phase 2b results in acute pancreatitis for lead […]

Read more

Acrux announces Gedeon Richter buyout of future Lenzetto® royalties for EUR4.1 million

/in

ASX Release: 23 January 2023 Melbourne, Australia; Acrux Limited (ASX:ACR) Link Here: Acrux today announced that it has concluded an agreement with Gedeon Richter Plc., one of its manufacturing and distribution partners, for Gedeon Richter to buy out the future royalties of Lenzetto® for contracted territories for EUR4.10 million, which at current rates of exchange […]

Read more

Graybug and CalciMedica Enter into Definitive Merger Agreement

/in

November 21, 2022 18:52 ET | Source: Graybug Vision, Inc.; CalciMedica Inc. Link here  Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into […]

Read more

Tragedy behind Australia’s world-class burns technology treatment RECELL: Robert Gottliebsen

/in

The Australian, Tuesday, November 8, 2022, Link Here: One of Australia’s best known, and most successful medical breakthroughs has been the burns treatment process developed in Western Australia, which was highlighted after the 2002 Bali bombings. But it is also one of the most tragic. The US has now embraced the Australian technology as its […]

Read more

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

/in

MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ Link here — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter 2022 and provided a corporate update. Second Quarter 2022 and Recent Developments: AP-PA02 advancing […]

Read more

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

/in

  Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]

Read more

Acrux’s sixth generic application accepted FDA for review

/in

Melbourne, Australia – 8 August 2022 Link here : Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the US Food and Drug Administration (FDA) has accepted for review Acrux’s application for a generic version (Abbreviated New Drug Application or ‘ANDA’) of cold sore treatment, Acyclovir Cream, 5%. Key Highlights Acrux has […]

Read more

Cynata Advances Clinical Trial in Diabetic Foot Ulcers

/in

Link to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]

Read more